HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Giorgio Parmiani Selected Research

HLA-A*02:01 antigen

11/2014A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma.
5/2013Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.
11/2008Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
12/2007Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide.
1/2005Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype.
5/2004Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens.
10/2003Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.
4/2003Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Giorgio Parmiani Research Topics

Disease

87Neoplasms (Cancer)
10/2018 - 03/2002
50Melanoma (Melanoma, Malignant)
01/2017 - 03/2002
13Colorectal Neoplasms (Colorectal Cancer)
04/2017 - 04/2003
4Neoplasm Metastasis (Metastasis)
02/2008 - 03/2002
4Adenocarcinoma
06/2005 - 11/2003
3Prostatic Neoplasms (Prostate Cancer)
01/2015 - 04/2007
2Neuroblastoma
10/2018 - 10/2003
2Colonic Neoplasms (Colon Cancer)
03/2013 - 04/2003
2Carcinoma (Carcinomatosis)
04/2007 - 10/2003
1Glioblastoma (Glioblastoma Multiforme)
04/2017
1Chills
11/2014
1Erythema
11/2014
1Tics (Tic)
02/2014
1Brain Neoplasms (Brain Tumor)
09/2012

Drug/Important Bio-Agent (IBA)

35AntigensIBA
01/2017 - 03/2002
25Peptides (Polypeptides)IBA
10/2018 - 06/2002
23VaccinesIBA
10/2018 - 03/2002
11CytokinesIBA
04/2015 - 03/2002
10EpitopesIBA
01/2017 - 06/2002
10MART-1 AntigenIBA
07/2010 - 10/2002
9Neoplasm Antigens (Tumor Antigens)IBA
10/2018 - 06/2002
9Heat-Shock Proteins (Heat-Shock Protein)IBA
11/2008 - 10/2002
8LigandsIBA
01/2017 - 04/2003
8Proteins (Proteins, Gene)FDA Link
01/2015 - 08/2003
8HLA-A*02:01 antigenIBA
11/2014 - 04/2003
8Interleukin-2 (IL2)IBA
05/2013 - 03/2002
7AntibodiesIBA
03/2016 - 03/2002
7Cancer VaccinesIBA
12/2012 - 04/2006
5Pharmaceutical PreparationsIBA
03/2012 - 11/2003
5Melanoma-Specific AntigensIBA
03/2007 - 06/2002
4HLA Antigens (Human Leukocyte Antigens)IBA
01/2017 - 10/2002
4Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
06/2007 - 05/2004
4Biological ProductsIBA
02/2007 - 03/2004
4Differentiation AntigensIBA
03/2005 - 10/2002
3Transforming Growth Factor beta (TGF-beta)IBA
04/2017 - 09/2006
3Interleukin-4 (Interleukin 4)IBA
04/2017 - 03/2002
3Biomarkers (Surrogate Marker)IBA
01/2017 - 11/2015
3T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA
01/2017 - 04/2003
3Immune Checkpoint InhibitorsIBA
01/2017 - 01/2015
3DNA (Deoxyribonucleic Acid)IBA
01/2017 - 08/2006
3IpilimumabIBA
02/2016 - 09/2012
3Epithelial Cell Adhesion MoleculeIBA
01/2014 - 10/2003
3Recombinant ProteinsIBA
03/2008 - 10/2003
3Interferon-alpha (Interferon Alfa)IBA
06/2007 - 08/2006
3vitespinIBA
08/2006 - 10/2002
3EnzymesIBA
08/2006 - 10/2003
3Monophenol Monooxygenase (Tyrosinase)IBA
08/2004 - 05/2003
2HLA-A2 Antigen (HLA A2 Antigen)IBA
10/2018 - 06/2003
2InterferonsIBA
04/2017 - 04/2002
2micaIBA
01/2017 - 05/2009
2fotemustine (Muphoran)IBA
02/2016 - 09/2012
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2014 - 06/2005
2Interleukin-15 (Interleukin 15)IBA
08/2012 - 08/2003
2Interleukin-12 (IL 12)IBA
10/2009 - 08/2007
2Carcinoembryonic AntigenIBA
10/2009 - 06/2005
2AutoantigensIBA
12/2007 - 05/2003
2Cytotoxins (Cytolysins)IBA
01/2007 - 11/2004
2SurvivinIBA
04/2006 - 08/2003
2CaspasesIBA
06/2005 - 04/2002
2sarcoma glycoprotein gp96 rejection antigensIBA
05/2005 - 10/2003
2Cisplatin (Platino)FDA LinkGeneric
11/2004 - 04/2002
2Immunoglobulin G (IgG)IBA
10/2003 - 03/2002
2PerforinIBA
08/2003 - 05/2003
2Granzymes (Granzyme)IBA
08/2003 - 05/2003
2Interleukin-7 (Interleukin 7)IBA
08/2003 - 03/2002
13-Phosphoinositide-Dependent Protein KinasesIBA
04/2017
1chondroitin sulfate proteoglycan 4IBA
04/2017
1Chimeric Antigen ReceptorsIBA
04/2017
1Aldehyde DehydrogenaseIBA
04/2017
1Monoclonal AntibodiesIBA
04/2017
1Dinoprostone (PGE2)FDA Link
04/2017
1Interleukin-10 (Interleukin 10)IBA
04/2017
1Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA
04/2017
1Interleukin-13IBA
04/2017
1STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
04/2017
1Interleukin-13 Receptors (Interleukin 13 Receptor)IBA
04/2017
1Growth Differentiation Factor 15IBA
04/2017
1B7-H1 AntigenIBA
04/2017
1CTLA-4 AntigenIBA
04/2017
1Calcibiotic Root Canal SealerIBA
01/2017
1Mitogen-Activated Protein KinasesIBA
11/2015
1Blocking AntibodiesIBA
11/2015
1Messenger RNA (mRNA)IBA
01/2015
1HLA-A Antigens (HLA-A)IBA
11/2014
1human CNGRC fusion protein tumor necrosis factor-alphaIBA
11/2014
1Thymidine KinaseIBA
06/2013
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
05/2013
1Histocompatibility Antigens Class IIBA
03/2013
1ChemokinesIBA
03/2012
1NGR peptideIBA
03/2012
1Indicators and Reagents (Reagents)IBA
09/2011

Therapy/Procedure

29Immunotherapy
04/2017 - 06/2002
18Therapeutics
04/2017 - 10/2003
8Biological Therapy
12/2013 - 04/2005
5Drug Therapy (Chemotherapy)
01/2014 - 05/2003
2Radiotherapy
11/2015 - 04/2007
2Heterologous Transplantation (Xenotransplantation)
09/2008 - 02/2008
1Castration
01/2015
1Aftercare (After-Treatment)
11/2014
1Intradermal Injections
07/2010